SAC May Have Seen Big Profit On Drug Test News

Jan 13 2014 | 12:42pm ET

Drug trials are at the heart of the insider-trading case against a former SAC Capital Advisors trader—and have earned the hedge fund more than $200 million this year already.

SAC owned nearly 1 million shares of Intercept Pharmaceuticals at the end of September. The stock nearly tripled in value on Thursday after the company announced a positive result of a liver-disease drug.

It is unclear whether SAC still holds its Intercept shares; the firm has been returning outside capital after pleading guilty to insider-trading charges. SAC first bought Intercept shares in the second quarter, boosting its stake to more than 988,000 shares by the end of the third.

The potentially big gain would rival the amount SAC allegedly earned or saved trading on confidential tips about drug trials received by former portfolio manager Mathew Martoma. Martoma is currently on trial.


In Depth

Fund Focus: Asian Frontier Capital Offers U.S. Investors Access To Untapped Markets

Mar 2 2015 | 6:47am ET

Hong-Kong based asset manager Asian Frontier Capital is making a capital raising...

Lifestyle

Hedge Fund Manager Out as Minnesota Wild Minority Owner

Feb 25 2015 | 2:45pm ET

New York hedge fund manager Philip Falcone is no longer a minority owner of the...

Guest Contributor

Risk Management: The Due Diligence Challenge And Branding Opportunity

Mar 2 2015 | 8:41am ET

The hedge fund firms that make it easier for prospective investors to gain comfort...

 

Editor's Note